Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
for Breast Cancer
51 locations incl. Mobile
Sponsor: Greenwich LifeSciences, Inc.
Sex: All·Age: 18 - 100
Code: NCT05232916·Phase 3·Recruiting